Gene signature validated for oral cancer metastases

Gene signature validated for oral cancer metastases
A multigene signature effectively predicts the presence of lymph node metastases in squamous cell carcinoma of the oral cavity and oropharynx, according to a study published online Oct. 8 in the Journal of Clinical Oncology.

(HealthDay)—A multigene signature effectively predicts the presence of lymph node metastases in squamous cell carcinoma of the oral cavity (OSCC) and oropharynx (OPSCC), according to a study published online Oct. 8 in the Journal of Clinical Oncology.

Sander R. van Hooff, from the University Medical Center Utrecht in the Netherlands, and colleagues used a diagnostic DNA microarray to evaluate a previously reported multigene signature for distinguishing metastasizing from non-metastasizing (N0) OSCC and OPSCC in 222 patients from all head and neck oncology centers in the Netherlands.

The researchers found that the negative predictive value was 72 percent for the diagnostic signature in the entire validation cohort. In a subset of early-stage (cT1 to T2N0) OSCC (101 patients), the signature performed well, with a negative predictive value of 89 percent.

"Combining current with the expression signature would decrease the rate of undetected nodal metastases from 28 to 11 percent in early-stage OSCC. This should be sufficient to enable clinicians to refrain from elective neck treatment," the authors write. "A new clinical decision model that incorporates the expression signature is therefore proposed for testing in a prospective study, which could substantially improve treatment for this group of patients."

One author disclosed to the diagnostic company Agendia.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

add to favorites email to friend print save as pdf

Related Stories

Gene signature predicts oral cancer recurrence

Oct 11, 2011

Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

10 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

16 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

16 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments